Cloning and characterization of the novel chimeric gene p53/FXR2 in the acute megakaryoblastic leukemia cell line CMK11-5

Tohoku Journal of Experimental Medicine

Volumn 209, Issue 3, 2006, Pages 169-180

  Kanezaki, Rika ^a   Toki, Tsutomu ^a   Xu, Gang ^a,b   Narayanan, Ramswamy ^c   Ito, Etsuro ^a  

^a HIROSAKI UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

^c FLORIDA ATLANTIC UNIVERSITY   (United States)

Author keywords

Acute megakaryoblastic leukemia; Down syndrome; Fusion protein; FXR2; p53

Indexed keywords

CHIMERIC PROTEIN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE INHIBITOR 1; ETOPOSIDE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X MENTAL RETARDATION PROTEIN 2; HYBRID PROTEIN; MESSENGER RNA; PROTEIN P53; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ACUTE MEGAKARYOCYTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CELL NUCLEUS; CELL TRANSFORMATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DNA ISOLATION; DOWN SYNDROME; EXPRESSION VECTOR; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE REARRANGEMENT; GENE STRUCTURE; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; LEUKEMOGENESIS; MALIGNANT TRANSFORMATION; MOLECULAR CLONING; MOLECULAR DYNAMICS; NONHUMAN; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TRANSACTIVATION; WESTERN BLOTTING; WILD TYPE;

ANIMALS; BASE SEQUENCE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CERCOPITHECUS AETHIOPS; CLONING, MOLECULAR; COS CELLS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA TOPOISOMERASES, TYPE II; ETOPOSIDE; GENE EXPRESSION PROFILING; GENES, P53; HUMANS; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; MICE; MOLECULAR SEQUENCE DATA; MUTANT CHIMERIC PROTEINS; NIH 3T3 CELLS; RNA-BINDING PROTEINS;

EID: 33745208430     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.209.169     Document Type: Article

References (36)

1. Adachi, M., Ryo, R., Sato, T. & Yamaguchi, N. (1991) Platelet factor 4 gene expression in a human megakaryocytic leukemia cell line (CMK) and its differentiated subclone (CMK11-5). Exp.Hematol., 19, 923-927.
2. Ahuja, H., Bar-Eli, M., Arlin, Z., Advani, S., Allen, S.L., Goldman, J., Snyder, D., Foti, A. & Cline, M. (1991) The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J. Clin. Invest., 87, 2042-2047.
3. Chipuk, J.E., Maurer, U., Green, D.R. & Schuler, M. (2003) Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell, 4, 371-481.
4. Chipuk, J.E., Kuwana, T., Bouchier-Hayes, L., Droin, N.M., Newmeyer, D.D., Schuler, M. & Green, D.R. (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science, 303, 1010-1014.
5. Drexler, H.G. (2004) Malignant hematopoietic cell lines: in vitro models for the study of myelodysplastic syndromes. Leuk. Res., 24, 109-115.
6. Eberhart, D.E., Malter, H.E., Feng, Y. & Warren, T. (1996) The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum. Mol. Genet., 5, 1083-1091.
7. El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., Mercer, W.E., Kinzler, K. & Vogelstein, B. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
8. El-Deiry, W.S., Harper, J.W., O'Connor, P.M., Velculescu, V.E., Canman, C.E., Jackman, J., Pietenpol, J.A., Burrell, M., Hill, D.E., Wang, Y., Wiman, K.G., Mercer, W.E., Kastan, M.B., Kohn, K.W, Elledge, S.J., Kinzler, K.W. & Vogelstein, B. (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res., 54, 1169-1174.
9. El-Deiry, W.S., Tokino, T., Waldman, T., Oliner, J.D., Velculescu, V.E., Burrell, M., Hill, D.E., Healy, E., Rees, J.L., Hamilton, S.R., Kinzler, K.W. & Vogelstein, B. (1995) Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55, 2910-2919.
10. Fan, S., El-Deiry, W.S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A.J., Jr., Magrath, I., Kohn, K.W. & O'Connor, P.M. (1994) p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54, 5824-5830.
11. Groet, J., McElwaine, S., Spinelli, M., Rinaldi, A., Burtscher, I., Mulligan, C., Mensah, A., Cavani, S., Dagna-Bricarelli, F., Basso, G., Cotter, F.E. & Nizetic, D. (2003) Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet, 361, 1617-1620.
12. Harris, C.C. (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J. Natl. Cancer Inst., 8, 1442-1455.
13. Hitzler, J.K., Cheung, J., Li, Y., Scherer, S.W. & Zipursky, A. (2003) GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood, 101, 4301-4304.
14. Kastan, M.B., Onyekwere, O., Sindransky, D., Vogelstein, B. & Craig, R.W. (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51, 6304-6311.
15. Kawamura, M., Kikuchi, A., Kobayashi, S., Hanada, R., Yamamoto, K., Horibe, K., Shikano, T., Ueda, K., Hayashi, K., Sekiya, T. & Hayashi, Y. (1995) Mutations of the p53 and ras genes in childhood t(1; 19)-acute lymphoblastic leukemia. Blood, 85, 2546-2552.
16. Kirsch, D. & Kastan, M. (1998) Tumor-suppressor p53: implications for tumor development and prognosis. J. Clin. Oncol., 16, 3158-3168.
17. Krug, U., Ganser, A. & Koeffler, H.P. (2002) Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene, 21, 3475-3495.
18. Malkin, D., Brown, E.J. & Zipursky, A. (2000) The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome. Cancer Genet. Cytogenet., 116, 1-5.
19. Maltzman, W. & Czyzyk, L. (1984) UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. Mol. Cell. Biol., 4, 189-1594.
20. Masuda, H., Miller, C., Koeffler, H.P., Battifora, H. & Cline, M.J. (1987) Rearrangement of the p53 gene in human osteogenic sarcomas. Proc. Natl. Acad. USA, 84, 7716-7719.
21. Mundschau, G., Gurbuxani, S., Gamis, A.S., Greene, M.E., Arceci, R.J. & Crispino, J.D. (2003) Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood, 101, 4298-4300.
22. Rainis, L., Bercovich, D., Strehl, S., Teigler-Schlegel, A., Stark, B., Trka, J., Amariglio, N., Biondi, A., Muler, I., Rechavi, G., Kempski, H., Haas O.A. & Izraeli, S. (2003) Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood, 102, 981-986.
23. Rotter, V., Abutbul, H. & Ben-Ze'ev, A. (1983) P53 transformation-related protein accumulates in the nucleus of transformed fibroblasts in association with the chromatin and is found in the cytoplasm of non-transformed fibroblasts. EMBO J., 2, 1041-1047.
24. Sakaguchi, S., Yokokawa, Y., Hou, J., Zhang, X.L., Li, X.P., Li, S.S., Li, X.X., Zhu, D.C., Kamijima, M., Yamanoshita, O. & Nakajima, T. (2005) Environmental exposure and p53 mutations in esophageal cancer patients in areas of low and high incidence of esophageal cancer in China. Tohoku J. Exp. Med., 207, 313-324.
25. Sambrook, J., Fritsch, E. F. & Maniatis, T. (1989) Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
26. Sato, T., Fuse, A., Eguchi, M., Hayashi, Y., Ryo, R., Adachi, M., Kishimoto, Y., Teramura, M., Mizoguchi, H., Shima, Y., Komori, I., Sunami, S., Okimoto, Y. & Nakajima, H. (1989) Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryoblastic leukaemia. Br. J. Haematol., 72, 184-190.
27. Shaulsky, G., Goldfinger, N., Ben-Ze'ev, A. & Rotter, V. (1990) Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell. Biol., 10, 6565-6577.
28. Siomi, M.C., Siomi, H., Sauer, W.H., Srinivasan, S., Nussbaum, R.L. & Dreyfuss, G. (1995) FXR1, an autosomal homolog of the fragile X mental retardation gene. EMBO J., 14, 2401-2408.
29. Spandidos, D.A. & Wilkie, N.M. (1984) Malignant transformation of early passage rodent cells by a single mutated human oncogene. Nature, 310, 469-475.
30. Sugimoto, K., Toyoshima, H., Sakai, R., Miyagawa, K., Hagiwara, K., Ishikawa, F., Takaku, F., Yazaki, Y. & Hirai, H. (1992) Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood, 79, 2378-2383.
31. Tamanini, F., Bontekoe, C., Bakker, C.E., van Unen, L., Anar, B., Willemsen, R., Yoshida, M., Galjaard, H., Oostra, B.A. & Hoogeveen, A.T. (1999) Different targets for the fragile X-related proteins revealed by their distinct nuclear localizations. Hum. Mol. Genet., 8, 863-869.
32. Tamanini, F., Kirkpatrick, L.L., Schonkeren, J., van Unen, L., Bontekoe, C., Bakker, C., Nelson, D.L., Galjaard, H., Oostra, B.A. & Hoogeveen, A.T. (2000) The fragile X-related proteins FXR1P and FXR2P contain a functional nucleolar-targeting signal equivalent to the HIV-1 regulatory proteins. Hum. Mol. Genet., 9, 1487-1493.
33. Wechsler, J., Greene, M., McDevitt, M.A., Anastasi, J., Karp, J.E., Le Beau, M.M. & Crispino, J.D. (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat. Genet., 32, 148-152.
34. Xu, G., Nagano, M., Kanezaki, R., Toki, T., Hayashi, Y., Taketani, T., Taki, T., Mitui, T., Koike, K., Kato, K., Imaizumi, M., Sekine, I., Ikeda, Y., Hanada, R., Sako, M., Kudo, K., Kojima, S., Ohneda, O., Yamamoto, M. & Ito, E. (2003) Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down's syndrome. Blood, 15, 2960-2968.
35. Zhang, Y., O'Connor, J.P., Siomi, M.C., Srinivasan, S., Dutra, A., Nussbaum, R.L. & Dreyfuss, G. (1995) The fragile X mental retardation syndrome protein interacts with novel homologs FXR1 and FXR2. EMBO J., 14, 5358-5366.
36. Zipursky, A., Poon, A. & Doyle, J. (1992) Leukemia in Down syndrome: a review. Ped. Hemat. Oncol., 9, 139-149.